CAR-NK Therapy for Systemic Lupus Erythematosus: Expanding Cell Therapy Beyond Cancer to Autoimmune Diseases

Over the past decade, chimeric antigen receptor (CAR)-based cell therapies have transformed the treatment of hematologic malignancies. As research continues to advance, these engineered immune cell therapies are expanding beyond oncology into autoimmune diseases. Among the emerging approaches, CAR-engineered natural killer (CAR-NK) therapy has attracted significant attention due to its promising safety profile, scalable manufacturing potential, and ability to selectively eliminate disease-causing immune cells.

Systemic lupus erythematosus (SLE), a chronic autoimmune disease characterized by immune dysregulation and multi-organ inflammation, has become one of the most promising indications for this innovative therapeutic strategy.

Understanding Systemic Lupus Erythematosus

Systemic lupus erythematosus is a complex autoimmune disease in which the immune system mistakenly attacks healthy tissues. Loss of immune tolerance leads to the production of autoantibodies, such as anti-double-stranded DNA (anti-dsDNA) antibodies, which form immune complexes and trigger chronic inflammation in organs including the kidneys, skin, joints, and nervous system.

Current treatment typically relies on corticosteroids, immunosuppressive agents, and biologic therapies. Although these treatments can reduce disease activity, many patients continue to experience relapses, long-term organ damage, and treatment-related adverse effects. As a result, there remains a significant unmet need for therapies capable of restoring immune balance rather than simply suppressing immune responses.

What Is CAR-NK Therapy?

CAR-NK therapy involves genetically engineering natural killer (NK) cells to express chimeric antigen receptors (CARs), enabling them to recognize and eliminate specific target cells with enhanced precision.

Unlike conventional therapies that broadly suppress immune function, CAR-NK therapy aims to selectively remove pathogenic immune cells while preserving much of the normal immune system.

Compared with CAR-T therapy, CAR-NK offers several potential advantages:

• Improved safety: Lower risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity.

• Off-the-shelf potential: NK cells can be derived from healthy donors, umbilical cord blood, induced pluripotent stem cells (iPSCs), or established cell lines, supporting standardized large-scale manufacturing.

• Broader immune regulation: In addition to directly killing target cells, NK cells produce cytokines that help regulate the immune microenvironment.

These characteristics make CAR-NK an attractive platform not only for cancer treatment but also for immune-mediated diseases such as SLE.

How CAR-NK Therapy May Treat Lupus

In systemic lupus erythematosus, abnormal B cells play a central role in disease progression by producing autoantibodies and sustaining chronic immune activation.

Most CAR-NK therapies under development are designed to target B-cell surface markers such as CD19 or CD20. Once these engineered NK cells recognize pathogenic B cells, they release perforin and granzymes that induce rapid cell death, thereby reducing the production of harmful autoantibodies.

Beyond direct cytotoxicity, NK cells also secrete immune-regulating cytokines that may help restore immune homeostasis. By eliminating disease-driving B cells while modulating the immune environment, CAR-NK therapy has the potential to "reset" abnormal immune responses instead of merely controlling symptoms.

CAR-NK vs. CAR-T Therapy

Although CAR-T therapy has shown encouraging results in severe autoimmune diseases, CAR-NK therapy may offer several practical advantages.

These advantages could make CAR-NK therapy more accessible and potentially more suitable for chronic autoimmune diseases requiring safer long-term management.

Clinical Progress

CAR-NK therapy for systemic lupus erythematosus remains in the early stages of clinical development. Most evidence currently comes from preclinical studies and early-phase clinical trials.

Experimental studies have demonstrated that CAR-NK cells targeting pathogenic B cells can significantly reduce autoantibody production and improve disease-related immune biomarkers. Early clinical observations also suggest a favorable safety profile, with fewer severe immune-related toxicities than those commonly associated with CAR-T therapy.

Researchers are now investigating additional therapeutic targets, including BCMA, while optimizing CAR designs through cytokine engineering, such as IL-15 expression, to enhance cell persistence and therapeutic durability.

Although further clinical validation is required, these advances indicate that CAR-NK therapy is progressing steadily from proof-of-concept toward broader clinical application.

Future Perspectives

Several developments are expected to shape the future of CAR-NK therapy:

• Multi-target CAR designs to improve treatment efficacy.

• Enhanced NK-cell persistence through genetic engineering.

• Combination strategies with biologics or immunomodulatory therapies.

• Universal, off-the-shelf CAR-NK products to improve accessibility and reduce manufacturing costs.

As cell engineering technologies continue to evolve, CAR-NK therapy has the potential to become an important component of precision medicine for autoimmune diseases.

Conclusion

CAR-NK therapy represents a promising new direction in autoimmune disease treatment. Rather than relying solely on long-term immunosuppression, this approach seeks to selectively eliminate pathogenic immune cells and restore immune balance through engineered cellular immunity.

Although clinical development is still in its early stages, growing scientific evidence suggests that CAR-NK therapy may become an important therapeutic option for systemic lupus erythematosus and other immune-mediated disorders in the future.

About DengYue

DengYue Medicine is an international pharmaceutical solutions provider committed to connecting healthcare partners with innovative medicines and emerging therapeutic technologies. By closely monitoring advances in cell therapy, gene therapy, and precision medicine, DengYue Pharma helps global partners stay informed about the latest developments in pharmaceutical innovation and international healthcare collaboration.